

# CLINICAL SCIENCE

## Guidance for Authors 1998

### CONTENTS

	<i>page</i>
<b>1. Policy of the journal</b>	
1.1. Scope . . . . .	i
1.2. Availability on the World Wide Web (WWW) . . . . .	i
1.3. The editorial process . . . . .	i
1.4. Ethics of investigations . . . . .	i
1.5. Originality of papers . . . . .	ii
<b>2. Submission of Manuscripts: General Information and Format</b>	
2.1. General . . . . .	ii
2.2. Use of authors' diskettes . . . . .	ii
2.3. Full Papers . . . . .	iii
2.4. Rapid Communications . . . . .	iii
2.5. Correspondence . . . . .	iii
2.6. Editorial Reviews . . . . .	iv
2.7. Comments . . . . .	iv
2.8. Arrangements for large amounts of information . . . . .	iv
2.9. Proof corrections . . . . .	iv
2.10. Offprints . . . . .	iv
2.11. Availability on MEDLINE and from Adonis . . . . .	iv
<b>3. Miscellaneous Notes</b>	
3.1. Abbreviations . . . . .	iv
3.2. Anatomical nomenclature . . . . .	iv
3.3. Animals, plants and micro-organisms . . . . .	iv
3.4. Biochemical nomenclature . . . . .	iv
3.5. Buffers and salts . . . . .	iv
3.6. Computer modelling . . . . .	iv
3.7. Doses . . . . .	iv
3.8. Enzymes . . . . .	iv
3.9. Evaluation of measurement procedures . . . . .	v
3.10. Figures and Tables . . . . .	v
3.11. Footnotes . . . . .	v
3.12. 'Homology' . . . . .	v
3.13. Isotope measurements . . . . .	vi
3.14. Radionuclide applications in man . . . . .	vi
3.15. Methods . . . . .	vi
3.16. Nomenclature of disease . . . . .	vi
3.17. Powers in Tables and Figures . . . . .	vi
3.18. References . . . . .	vi
3.19. Solutions . . . . .	vi
3.20. Spectrophotometric data . . . . .	vi
3.21. Spelling . . . . .	vi
3.22. Statistics . . . . .	vii
3.23. Trade names . . . . .	vii
<b>4. Units: The SI System</b> . . . . .	vii
<b>5. Abbreviations, Conventions etc.</b> . . . . .	vii

### I. POLICY OF THE JOURNAL

#### I.1. Scope

*Clinical Science* publishes papers in the field of clinical investigation, provided they are of a suitable standard and contribute to the advancement of knowledge in this field. The term 'clinical investigation' is used in its broadest sense to include studies in animals and the whole range of biochemical, physiological, immunological and other approaches that may have relevance to disease in man. Studies which are confined to normal subjects, or animals, or are purely methodological in nature may be acceptable. The material presented should permit conclusions to be drawn and should not be only of a preliminary nature. The journal publishes five types of manuscript, namely invited Editorial Reviews, Full Papers, Rapid Communications, Correspondence and invited Comments. In addition, *Clinical Science* publishes abstracts of the proceedings of the Medical Research Society (as Supplements) and also the Bayer Lecture.

#### I.2. Availability on the World Wide Web (WWW)

Abstracts of all articles are available on the journal's home page on the WWW (<http://cs.portlandpress.co.uk>). The journal will become fully online during 1998.

#### I.3. The editorial process

Membership of the Editorial Board covers as wide a range of interests as possible.

A submitted paper is considered by an appropriate editor together with (usually) two Referees from outside the membership of the Board. The Editor returns it with a recommendation to the Editor in Chief or Regional Editor, who then writes formally to the authors. The ultimate responsibility of acceptance for publication lies with the Editor in Chief.

Authors may suggest potential referees for their papers in the submission letter. The journal is under no obligation to follow such suggestions, but, if it does so, only one of the referees will be chosen from the authors' nominations, as the other referee will be selected independently.

#### I.4. Ethics of investigations

(a) Human subjects. Authors must state in the text of their paper that the research has been carried out in accordance with the Declaration of Helsinki (1989) of the World Medical Association, and has been approved by the Ethics Committee of the institution in which the work was performed. Consent **must** be obtained from each patient or subject after full explanation of the purpose, nature and risk of all procedures used, and the fact that such

## Volume 94

### AUTHOR INDEX

- Aalkjaer, C. 359–365  
Abbott, M. 671–676  
Adams, C. 121–127  
Adams, M. 359–365  
Åkerblom, H. K. 263–269  
Akinola, A. 49–55  
Aliot, E. 485–492  
Andreu, A. L. 447–452  
Arnal, M. 413–423  
Arner, P. 71–77  
Atherton, J. 339–346  
Avkiran, M. 359–365
- Baandrup, U. 141–147  
Badier, M. 279–286  
Baines, M. 197–201  
Balcke, P. 431–435  
Ballinger, A. 479–483  
Banning, A. P. 43–48  
Bär, P. R. 271–278  
Barber, C. 157–163  
Barnes, P. J. 557–572  
Barron, J. 591–599  
Bauersachs, R. 255–261  
Bayle, G. 413–423  
Beck, O. 663–670  
Beilin, L. J. 573–578  
Belch, J. J. F. 537–540  
Bell, J. I. 473–478  
Bendahan, D. 279–286  
Berlanga, J. 219–223  
Bernardi, L. 615–621  
Besser, R. 479–483  
Bethune, D. W. 35–41  
Beyer, J. 255–261  
Blanco, I. 189–195  
Bolinder, J. 71–77  
Bone, J. M. 425–430  
Bord, S. 549–555  
Bottomley, M. J. 395–404  
Boyer, J. 181–188  
Brain, A. 203–206  
Brenchley, P. E. C. 395–404  
Brett, S. E. 129–134  
Breuillé, D. 413–423  
Bruda, N. L. 505–509  
Brunini, T. M. C. 43–48  
Bruntz, J. F. 485–492  
Buckley, M. G. 591–599  
Bund, S. J. 225–229, 231–238  
Burrell, L. M. 517–523
- Butler, R. 175–180  
Buus, N. H. 141–147
- Caballero, M. E. 219–223  
Caillol, N. 181–188  
Calder, A. G. 321–331  
Calder, P. C. 303–311  
Carney, B. I. 65–70  
Chan, C.-C. 367–371  
Chang, F.-Y. 367–371, 645–650  
Charlesworth, J. A. 511–516  
Chati, Z. 485–492  
Chen, M.-F. 29–34  
Cheng, Y.-R. 645–650  
Childhood Diabetes in Finland Study Group 263–269  
Chilvers, E. R. 461–471  
Chowienczyk, P. J. 129–134  
Chu, C.-J. 367–371  
Ciuffo, R. 525–529  
Clement, D. L. 57–63  
Coghlan, J. P. 149–155  
Condliffe, A. M. 461–471  
Confort-Gouny, S. 279–286  
Conway, M. 43–48  
Cooke, R. W. I. 197–201  
Costigan, M. 425–430  
Cozzone, P. J. 279–286  
Criado, M. 637–643  
Critchley, M. 425–430  
Croft, K. D. 573–578
- d'Annunzio, G. 615–621  
Das, A. M. 493–504  
Davis, J. 303–311  
Davy, K. P. 579–584  
Day, J. M. 671–676  
De Buyzere, M. L. 57–63  
de Dios, I. 293–301  
De Jong, M. B. 271–278  
Derckx, F. H. 165–173  
DeSouza, C. A. 579–584  
De Souza, G. 321–331  
Devynck, M.-A. 79–85  
Dhir, N. K. 87–99  
Dimmitt, S. B. 573–578  
Dodd, C. M. 541–547  
Dodic, M. 149–155  
Drieghe, B. 57–63  
Drury, J. A. 197–201
- Duggan, K. A. 511–516  
Duprez, D. A. 57–63
- Eiken, P. 405–412  
Elder, J. B. 87–99  
Elia, M. 313–319  
Ellory, J. C. 43–48  
Esler, M. D. 383–393  
Esteller, A. 637–643  
Ethévenot, G. 485–492
- Farthing, M. 479–483  
Finch, C. F. 671–676  
Flatebø, T. 453–460  
Forst, T. 255–261  
Fratino, P. 615–621  
Frenneaux, M. P. 339–346  
Fujii, T. 531–535
- Garcia, S. R. 225–229  
García-Arumí, E. 447–452  
Ghahary, A. 541–547  
Gibson, P. R. 671–676  
Gil-Martinez, E. 189–195  
Gocke, C. 657–661  
Goggins, M. 677–685  
Grabietz, P. D. 271–278  
Granado, F. 189–195  
Green, L. 65–70  
Griffin, G. E. 321–331  
Grime, J. S. 425–430  
Grouzmann, E. 591–599  
Guha, S. 65–70  
Guieu, R. 181–188  
Guillot, C. 279–286
- Haenen, J. H. 651–656  
Hallyburton, E. 479–483  
Hamada, M. 21–27  
Hambleton, I. 111–120  
Hanssen, H. 43–48  
Harm, F. 431–435  
Harrap, S. B. 337–338  
Hauser, A.-C. 431–435  
Hayashi, Y. 585–590  
Hellström, P. M. 663–670  
Henney, A. 103–110  
Hill, G. E. 505–509  
Hirata, K. 531–535  
Hirose, H. 633–636  
Hiwada, K. 21–27

- Hjemdahl, P. 663–670  
Hodge, G. 511–516  
Holland, S. 203–206  
Horowitz, M. 65–70  
Hou, M.-C. 645–650  
Hsu, H.-C. 29–34  
Huang, Y.-T. 645–650  
Hughes, A. 425–430  
Humphries, S. 103–110  
Hung, J. 437–445  
Hunt, J. V. 35–41  
Hurlbert, B. J. 505–509
- Ilonen, J. 263–269  
Ilton, M. K. 437–445  
Imms, F. J. 353–358  
Iqbal, S. J. 203–206  
Iribu, G. 585–590  
Iyawe, V. I. 353–358
- Jackson, M. J. 1  
James, L. A. 313–319  
James, M. A. 245–253  
Jammes, Y. 279–286  
Janssen, M. C. H. 651–656  
Jenkins, B. S. 129–134  
Jennings, G. L. 383–393  
Jewell, D. P. 473–478  
Johansen, B. 453–460  
Johnston, C. I. 517–523  
Jonason, T. 239–243  
Jones, K. L. 65–70  
Jones, P. P. 579–584  
Jordan, J. 5
- Kahr, O. 359–365  
Kaiser, M. 359–365  
Kakkar, R. 623–632  
Kalra, J. 623–632  
Kanazawa, H. 531–535  
Kangawa, K. 21–27, 135–139, 585–590  
Kawai, T. 633–636  
Kawakami, H. 21–27  
Kelly, M. 359–365  
Kelly, P. 479–483  
Kerckhoffs, D. A. J. M. 71–77  
Kilias, D. 671–676  
King, P. 157–163  
Kirk, G. 537–540  
Kitchen, E. 461–471  
Kneale, B. J. 129–134  
Knip, M. 263–269  
Kojima, S. 135–139  
Kolthoff, N. 405–412  
Komulainen, J. 263–269  
Kon, M. 271–278  
Kong, M.-F. 157–163
- Kosakai, Y. 585–590  
Kristensen, B. 405–412  
Kroese, A. B. A. 271–278  
Kröger, K. 657–661  
Kudoh, S. 531–535  
Kuneš, J. 79–85  
Kunt, T. 255–261  
Kuramochi, M. 135–139  
Kuro, M. 585–590  
Kurpad, A. V. 321–331  
Küstner, E. 255–261
- Lambert, G. W. 383–393  
Langley-Evans, S. C. 373–381  
Le Quan Sang, K. H. 79–85  
Lean, M. E. J. 121–127  
Lee, C.-M. 29–34  
Lee, D.-Y. 367–371  
Lee, F.-Y. 645–650  
Lee, S.-D. 367–371, 645–650  
Lee, Y.-T. 29–34  
Leen, E. 121–127  
Leppert, J. 239–243  
Leuzzi, S. 615–621  
Levieux, D. 413–423  
Lin, H.-C. 367–371, 645–650  
Lind, L. 601–607  
Lodos, J. 219–223  
Lodwick, D. 359–365  
Lombardo, D. 181–188  
Loon, N. R. 287–292  
López-Hellín, J. 447–452  
López-Novoa, J. M. 637–643  
Lord, R. 101  
Lördal, M. 663–670  
Lorini, R. 615–621  
Lounamaa, R. 263–269  
Lunn, P. G. 313–319  
Lye, M. 493–498
- Macallan, D. C. 321–331  
Macdonald, I. A. 157–163  
MacGregor, G. A. 591–599  
Mahadeva, N. 359–365  
Makarious, M. M. 511–516  
Maltby, P. 425–430  
Mann, G. E. 43–48  
Manso, M. A. 293–301  
Mantha, S. V. 623–632  
Maple, C. 537–540  
Marshall, J. M. 111–120  
Martín de Arriba, A. 637–643  
Maruyama, H. 633–636  
Mas, E. 181–188  
Mathias, C. J. 49–55  
Matsuo, H. 21–27, 135–139, 585–590  
Matsuoka, H. 135–139
- May, C. N. 149–155  
McFadden, E. R. 525–529  
McKenna, W. J. 339–346  
McLaren, M. 537–540  
McNurlan, M. A. 321–331  
Melsom, M. N. 453–460  
Mendes Ribeiro, A. C. 43–48  
Michielsen, W. 57–63  
Middleton, S. 313–319  
Millan, I. 189–195  
Millgård, J. 601–607  
Minamino, N. 21–27, 585–590  
Misso, N. L. A. 437–445  
Missouris, C. G. 591–599  
Miyata, A. 135–139, 585–590  
Mohamed-Ali, V. 609–614  
Mohan, J. 111–120  
Morris, A. D. 175–180  
Morris-Thurgood, J. 339–346  
Mulvany, M. J. 141–147
- Nakamura, K. 633–636  
Nelson, J. A. 525–529  
Newsholme, E. A. 303–311  
Nicolaysen, G. 453–460  
Nielsen, S. P. 405–412  
Nishikimi, T. 135–139, 585–590  
Nyborg, N. C. B. 141–147  
Nycyk, J. A. 197–201
- Obled, C. 413–423  
Olmedilla, B. 189–195  
Oreffo, R. O. C. 549–555  
Orfao, A. 293–301
- Paganga, G. 129–134  
Pala, H. 303–311  
Panerai, R. B. 245–253  
Parkes, M. 473–478  
Parkin, H. 157–163  
Pasqualini, E. 181–188  
Penny, M. 203–206  
Peters, A. M. 7–19  
Petyaev, I. M. 35–41  
Pfützner, A. 255–261  
Phillips, P. A. 517–523  
Playford, R. J. 219–223  
Pohlmann, T. 255–261  
Potter, J. F. 245–253  
Prasad, K. 623–632  
Pribasniġ, A. 431–435  
Puvi-Rajasingham, S. 49–55
- Radaelli, A. 615–621  
Radhi, J. 623–632  
Rambourdin, F. 413–423  
Ramirez, D. 219–223  
Reid, H. L. 111–120  
Reijonen, H. 263–269

- Reynolds, T. M. 203–206  
 Ringqvist, Å. 239–243  
 Ringqvist, I. 239–243  
 Risvanis, J. 517–523  
 Ritter, J. M. 129–134  
 Roberts, N. B. 43–48  
 Robertson, D. 5  
 Rodríguez-López, A. M. 637–643  
 Rojas-Hidalgo, E. 189–195  
 Rosella, O. 671–676  
 Rudofsky, G. 657–661  
 Russo, F. 353–358  
 Rustom, R. 425–430
- Sabbah, E. 263–269  
 Saito, I. 633–636  
 Salvan, A. M. 279–286  
 Salvucci, F. 615–621  
 Samani, N. J. 359–365  
 Sánchez-Rodríguez, A. 637–643  
 Saruta, T. 633–636  
 Satsangi, J. 473–478  
 Savage, M. W. 609–614  
 Scaramuzza, A. 615–621  
 Schalekamp, M. A. 165–173  
 Schelo, C. 657–661  
 Schenk, U. 255–261  
 Schragger, J. 87–99  
 Schwartz, S. 447–452  
 Scott, J. M. 677–685  
 Scott, P. G. 541–547  
 Seals, D. R. 579–584  
 Segal, M. B. 353–358  
 Serjeant, G. R. 111–120  
 Shannon, J. R. 5  
 Sheldon, R. S. 335–336  
 Shen, Y. J. 541–547  
 Shenkin, A. 425–430  
 Sherman, R. C. 373–381
- Shetty, P. S. 321–331  
 Shigematsu, Y. 21–27  
 Shimada, Y. 359–365  
 Shoji, S. 531–535  
 Shovlin, C. L. 207–218  
 Sidebotham, R. L. 87–99  
 Sinclair, A. 121–127  
 Singer, D. R. J. 591–599  
 Skowronski, M. E. 525–529  
 Smith, G. D. P. 49–55  
 Smith, P. 359–365  
 Spencer, J. 87–99  
 Stewart, D. J. 3–4  
 Struthers, A. D. 175–180
- Taberbero, M. D. 293–301  
 Taes, Y. 57–63  
 Tai, C.-C. 367–371  
 Takishita, S. 135–139, 585–590  
 Tattersall, R. B. 157–163  
 Taylor, M. L. 437–445  
 Ten Harkel, A. D. J. 347–352  
 Terp, K. 141–147  
 Thien, Th. 651–656  
 Thies, F. 303–311  
 Thomas, P. W. 111–120  
 Thompson, J. M. 383–393  
 Thompson, P. J. 437–445  
 Thomson, H. L. 339–346  
 Tonkin, A. 65–70  
 Torres, A. 219–223  
 Tredget, E. E. 541–547  
 Triffitt, J. T. 549–555  
 Tsai, Y.-T. 645–650
- Vähäsalo, P. 263–269  
 Valenzuela, C. 219–223  
 Valette, A. 181–188  
 van Asten, W. N. J. C. 651–656
- van der Heijden, E. P. A. 271–278  
 Vanhaverbeke, F. 57–63  
 Van Lieshout, J. J. 347–352  
 Veale, D. 537–540  
 Vicente, S. 293–301  
 Vuylsteke, A. 35–41
- Walker, M. M. 87–99  
 Wallén, H. 663–670  
 Walley, T. 493–498  
 Wallin, B. G. 383–393  
 Walsh, K. M. 121–127  
 Wang, S.-S. 367–371  
 Watson, C. J. 395–404  
 Webb, N. J. A. 395–404  
 Weimar, W. 165–173  
 Weir, D. G. 677–685  
 Werker, P. M. N. 271–278  
 Wieling, W. 347–352  
 Wiesholzer, M. 431–435  
 Wilcox, C. S. 287–292, 687  
 Williams, G. 609–614  
 Williams, P. D. 573–578  
 Wintour, E. M. 149–155  
 Wishart, J. M. 65–70  
 Wollersheim, H. 651–656  
 Wu, S.-L. 367–371
- Yamada, M. 531–535  
 Yaqoob, P. 303–311  
 Ye, S. 103–110  
 Yoshikawa, J. 531–535  
 Yoshikawa, T. 531–535  
 Yoshitomi, Y. 135–139  
 Young, G. P. 671–676
- Zannad, F. 485–492  
 Zicha, J. 79–85  
 Zietse, R. 165–173

# Volume 94

## SUBJECT INDEX

First and last page numbers of papers to which entries refer are given. Page numbers marked with an asterisk refer to Reviews.

- Acetylcholine**  
coronary arteries, hypertension 231–238  
endothelial dysfunction, hypercholesterolaemia 129–134  
neurovascular stimulation, diabetic neuropathy 255–261
- N*-Acetyl- $\beta$ -D-glucosaminidase**  
proteinuria, lisinopril 425–430
- Acquired immunodeficiency syndrome**  
leptin, anorexia 479–483
- Acute phase proteins**  
infection, protein metabolism 413–423
- Adenosine deaminase deficiency**  
polymorphism, haemorrhagic telangiectasia 207–218\*
- S*-Adenosylhomocysteine**  
brain, protein carboxymethylation 677–685
- S*-Adenosylmethionine**  
brain, protein carboxymethylation 677–685
- Adhesion**  
platelet P-selectin, neutrophil cathepsin G 437–445
- Adhesion molecule-1**  
inflammatory response, circadian rhythm 537–540
- Adipose tissue**  
lipolysis, glucose metabolism 71–77
- Adolescents**  
diabetes, cardiovascular reflexes 615–621  
haematopoiesis, leptin 633–636
- Adrenaline**  
isometric exercise, muscle sympathetic activity 383–393  
thermogenesis, energy expenditure 121–127
- Adrenomedullin**  
cardiac surgery, anaesthesia 585–590  
gene expression, cardiac hypertrophy 359–365  
hypertrophic cardiomyopathy, natriuretic peptides 21–28  
myocardial infarction, natriuretic peptides 135–139
- Aerobic exercise**  
heart rate variability, aging 579–584
- Aging**  
aerobic exercise, heart rate variability 579–584  
osteogenesis, colony forming units-fibroblastic 549–555
- Airway obstruction**  
cold exposure, asthma 525–529
- Airway occlusion**  
pulmonary blood flow distribution, blood gases 453–460
- Albumin**  
bile-salt-dependent lipase, glycation 181–188
- Alkaline phosphatase**  
colonic epithelium, butyrate enema 671–676  
hypophosphatasia, pyridoxal-5'-phosphate 203–206
- Ammonia excretion**  
proteinuria, lisinopril 425–430
- Anabolic block**  
tuberculosis, undernutrition 321–331
- Anaesthesia**  
adrenomedullin, cardiac surgery 585–590
- Angiotensin-converting enzyme**  
glomerular permeability, diabetes 165–173
- Angiotensin-converting enzyme inhibitors**  
diabetic nephropathy, hypertension 511–516  
maternal undernutrition, hypertension 337–338, 373–381  
proximal tubular hypercatabolism, lisinopril 425–430
- Anorexia**  
acquired immunodeficiency syndrome, leptin 479–483
- Antioxidant enzyme activity**  
oxidative stress, elderly 447–452
- Antioxidant enzymes**  
diabetes, liver 623–632
- Antioxidant status**  
preterm infants, lipid peroxidation 197–201
- Antioxidants**  
diabetes, dietary supplements 189–195  
hypercholesterolaemia, coronary artery disease 129–134  
low-density lipoprotein,  $\beta$ -blockers 573–578

- Aprotinin**  
 cardiopulmonary bypass, nitric oxide 505–509  
 renal tubular injury, lisinopril 425–430
- L-Arginine**  
 endothelial dysfunction, hypercholesterolaemia 129–134
- L-Arginine transport**  
 erythrocytes, heart failure 3–4, 43–48
- Asthma**  
 cold exposure, airway reactivity 525–529  
 glucocorticoids, gene transcription 557–572\*
- Atherosclerosis**  
 diabetes, glycation 181–188  
 vascular matrix remodelling, matrix metalloproteinases 103–110\*
- Athymic mice**  
 colon cancer, fish oil 303–311
- ATP synthase**  
 mitochondrion, heart muscle 499–504
- Atrial natriuretic peptide**  
 adrenomedullin, myocardial infarction 135–139  
 cardiac hypertrophy, gene expression 359–365  
 glomerular permeability, diabetes 165–173  
 heart failure 591–599  
 hypertrophic cardiomyopathy, adrenomedullin 21–28
- Atrial pacing**  
 myocardial ischaemia, thromboxane 29–34
- Autoantibodies**  
 diabetes, genetic susceptibility 263–269
- Autonomic failure**  
 blood pressure, exercise 5, 49–55  
 orthostatic hypotension 347–352
- Autonomic neuropathy**  
 diabetes, baroreflex sensitivity 615–621
- $\beta$ -blockers**  
 low-density lipoprotein, oxidation 573–578
- Baroreflex sensitivity**  
 diabetes, autonomic neuropathy 615–621  
 hypertension, elderly 245–253
- Bile-salt-dependent lipase**  
 albumin, glycation 181–188
- Blood clotting**  
 platelets, vascular endothelial growth factor 395–404
- Blood flow**  
 nitric oxide, insulin sensitivity 175–180
- Blood gases**  
 bronchial occlusion, pulmonary flow distribution 453–460
- Blood pressure**  
 baroreflex sensitivity, pressoreceptors 245–253
- captopril, maternal undernutrition 337–338, 373–381  
 chronic fatigue syndrome, heart rate variability 57–63  
 endothelium-dependent vasodilatation, noradrenaline 601–607  
 gastric emptying, diabetes mellitus 65–70  
 glucocorticoids, prenatal exposure 149–155  
 insulin resistance, hypertension 609–614  
 sympathetic denervation, exercise 5, 49–55
- Blood specimens**  
 factitious hyperkalaemia 101
- Body cooling**  
 flow-mediated dilatation, Raynaud's disease 239–243
- Body fat**  
 acquired immunodeficiency syndrome, leptin 479–483
- Body mass index**  
 insulin, leptin 633–636
- Bone**  
 osteoprogenesis, aging 549–555
- Bone mineral density**  
 lactation, pregnancy 405–412
- Brachial artery**  
 endothelium-dependent dilatation, Raynaud's disease 239–243
- Brain blood flow**  
 hyperventilation, isometric exercise 353–358
- Brain**  
 hypoglycaemia, lactate 157–163  
 protein carboxymethylation 677–685
- Brain natriuretic peptide**  
 adrenomedullin, myocardial infarction 135–139  
 heart failure 591–599  
 hypertrophic cardiomyopathy, adrenomedullin 21–28
- Bronchial occlusion**  
 pulmonary flow distribution, blood gases 453–460
- Bronchoalveolar lavage fluid**  
 interstitial lung disease, cytokeratins 531–535
- Bumetanide**  
 natriuretic response, metabolic alkalosis 287–292, 687
- Burns**  
 hypertrophic scar tissue, proteoglycans 541–547
- Butyrate enema**  
 colonic epithelium, cell proliferation 671–676
- Calcium**  
 hypertension, membrane microviscosity 79–85

- Calcium intake
  - bone mineral density, pregnancy 405–412
- Calcium ions
  - ATP synthase, heart muscle 499–504
- Captopril
  - maternal undernutrition, hypertension 337–338, 373–381
- Carbohydrate ingestion
  - lipolysis, adipose tissue 71–77
- Carbon tetrachloride
  - hepatic injury, epidermal growth factor 219–223
- Carboxymethylation
  - protein, brain 677–685
- Cardiac baroreflex sensitivity
  - aerobic exercise, aging 579–584
- Cardiac hypertrophy
  - adrenomedullin, gene expression 359–365
- Cardiac output
  - obesity, adrenaline 121–127
  - orthostatic hypotension, autonomic failure 347–352
- Cardiac surgery
  - adrenomedullin, anaesthesia 585–590
  - oxygen, plasma lipid 1, 35–41
- Cardiopulmonary bypass
  - adrenomedullin, anaesthesia 585–590
  - lipid-associated oxygen, blood 1, 35–41
  - nitric oxide, aprotinin 505–509
- Cardiovascular reflexes
  - diabetes, adolescents 615–621
- Cardiovascular response
  - obesity, thermogenesis 121–127
- Carotenoids
  - diabetes, dietary supplements 189–195
- Catalase
  - diabetes, oxidative stress 623–632
  - oxidative stress, elderly 447–452
- Catecholamines
  - heart failure 591–599
- Cathepsin
  - oxidative stress, elderly 447–452
- Cathepsin G
  - platelet–neutrophil adhesion, platelet P-selectin 437–445
- Cell proliferation
  - colonic epithelium, butyrate enema 671–676
- Cerebral blood flow
  - isometric exercise, hyperventilation 353–358
- Cerebral dysfunction
  - diabetes, lactate 157–163
- Chronic atrophic gastritis
  - mucins 87–99
- Chronic fatigue syndrome
  - heart rate variability, blood pressure 57–63
- Chronic ischaemic myocardial remodelling
  - N*<sup>G</sup>-nitro-L-arginine, coronary arteries 141–147
- Chronic lung disease
  - total antioxidant status, preterm infants 197–201
- Circadian rhythm
  - adhesion molecule-1, inflammatory response 537–540
- Circulatory reflex adjustment
  - orthostatic hypotension, autonomic failure 347–352
- Cirrhosis
  - nitric oxide, peripheral vascular resistance 637–643
  - portal hypertension, octreotide 367–371
- Clinical characteristics
  - diabetes, genetic susceptibility 263–269
- Cold exposure
  - airway obstruction, asthma 525–529
- Cold storage
  - muscle contractility, preservation solutions 271–278
- Colon cancer
  - fish oil, athymic mice 303–311
- Colonic epithelium
  - cell proliferation, butyrate enema 671–676
- Colony forming units-fibroblastic
  - osteogenesis, aging 549–555
- Colour Doppler sonography
  - venous thrombosis 657–661
- Congestive heart failure
  - adrenomedullin, natriuretic peptides 135–139
- Cooling
  - sickle cell disease, vascular response 111–120
- Coronary arteries
  - hypertension, acetylcholine 231–238
  - myocardial hypertrophy, nitric oxide 141–147
  - myogenic tone, nitric oxide 225–229
- Coronary artery disease
  - stromelysin expression, polymorphism 103–110\*
  - vitamin E, hypercholesterolaemia 129–134
- Coronary disease
  - low-density lipoprotein,  $\beta$ -blockers 573–578
- Coronary flow reserve
  - exercise capacity, dilated cardiomyopathy 485–492
- Crohn's disease
  - genetic susceptibility, major histocompatibility complex 473–478\*
- Cyclic GMP
  - endothelium-dependent dilatation, Raynaud's disease 239–243

- Cyclo-oxygenase  
myogenic tone, hypertension 225–229
- Cytokeratins  
bronchoalveolar lavage fluid, interstitial lung disease 531–535
- Decorin  
hypertrophic scar tissue, fibroblasts 541–547
- Deep venous thrombosis  
strain-gauge plethysmography, duplex scanning 651–656
- Deoxycorticosterone acetate-salt hypertension  
vasopressin receptors 517–523
- Diabetes  
adolescents, cardiovascular reflexes 615–621  
bile-salt-dependent lipase, glycation 181–188  
cerebral dysfunction, lactate 157–163  
fat-soluble vitamins, dietary supplements 189–195  
genetic susceptibility, autoantibodies 263–269  
glomerular permeability, angiotensin-converting enzyme 165–173  
neurovascular stimulation, nutritive capillary blood flow 255–261  
oxidative stress, liver 623–632  
postprandial hypotension, gastric emptying 65–70
- Diabetic nephropathy  
angiotensin-converting enzyme 165–173  
angiotensin-converting enzyme inhibitors, hypertension 511–516  
neurogenic inflammation, total skin blood flow 255–261
- Dietary lipids  
tumour growth, colon cancer 303–311
- Dietary supplements  
fat-soluble vitamins, diabetes 189–195
- Dilated cardiomyopathy  
coronary flow reserve, exercise capacity 485–492
- Diphenylhexatriene anisotropy  
membrane microviscosity, erythrocytes 79–85
- Direct electrical stimulation  
muscle contractility, preservation solutions 271–278
- Duplex scanning  
deep venous thrombosis, strain-gauge plethysmography 651–656
- Elderly  
hypertension, baroreflex sensitivity 245–253  
lymphocytes, oxidative stress 447–452  
temperature, haemodynamics 493–498
- Endoglin  
genetic mutation, haemorrhagic telangiectasia 207–218\*
- Endothelial dysfunction  
vitamin E, hypercholesterolaemia 129–134
- Endothelin-1  
hypertrophic cardiomyopathy, adrenomedullin 21–28
- Endothelium-dependent relaxation  
coronary arteries, hypertension 231–238  
vascular smooth muscle, nitric oxide 225–229
- Endothelium-dependent vasodilatation  
hypertension, noradrenaline 601–607  
Raynaud's disease, nitric oxide 239–243
- Endothelium-derived hyperpolarizing factor  
coronary arteries, hypertension 231–238
- Endotoxin  
cirrhosis, nitric oxide 637–643
- Energy expenditure  
thermogenesis, adrenaline 121–127
- Epidermal growth factor  
hepatic injury, carbon tetrachloride 219–223
- Erythrocytes  
L-arginine transport, heart failure 3–4, 43–48  
membrane microviscosity, hypertriglyceridaemia 79–85
- E-selectin  
inflammatory response, circadian rhythm 537–540
- Excitation–contraction coupling  
hypoxaemia, muscle fatigue 279–286
- Exercise  
heart rate variability, aging 579–584  
sympathetic denervation, blood pressure 5, 49–55
- Exercise capacity  
coronary flow reserve, dilated cardiomyopathy 485–492
- Exercise-induced hypotension  
venous capacitance, hypertrophic cardiomyopathy 335–336, 339–346
- Factitious hyperkalaemia  
blood specimens 101
- Fasting  
autonomic failure, blood pressure 5, 49–55
- Fat-soluble vitamins  
diabetes, dietary supplements 189–195
- Fatty acids  
tumour growth, colon cancer 303–311
- Fetal exposure  
low-protein diet, hypertension 337–338, 373–381



- Fibroblasts**  
hypertrophic scar tissue, decorin 541–547
- Fish oil**  
colon cancer, athymic mice 303–311
- Flow-mediated dilatation**  
Raynaud's disease, body cooling 239–243
- Free-radical production**  
preterm infants, antioxidant status 197–201
- Gas-exchange abnormality**  
bronchial occlusion, pulmonary flow distribution 453–460
- Gastric carcinoma**  
mucins 87–99
- Gastric emptying**  
postprandial hypotension, diabetes mellitus 65–70
- Gastrointestinal motility**  
small intestine, 5-hydroxytryptamine 663–670
- Gastrointestinal tract**  
Crohn's disease, genetic linkage 473–478\*  
glutaminase distribution, glutamine synthetase 313–319
- Gene expression**  
adrenomedullin, cardiac hypertrophy 359–365
- Gene transcription**  
glucocorticoids, inflammation 557–572\*  
vasopressin receptors, deoxycorticosterone acetate-salt hypertension 517–523
- Genetic linkage**  
inflammatory bowel disease, Crohn's disease 473–478\*
- Genetic mutation**  
adenosine deaminase deficiency, respiratory disease 207–218\*
- Genetic susceptibility**  
Chron's disease, major histocompatibility complex 473–478\*  
diabetes, autoantibodies 263–269
- Glomerular angiotensin-converting enzyme activity**  
angiotensin-converting enzyme inhibitors, diabetic nephropathy 511–516
- Glomerular permeability**  
diabetes, angiotensin-converting enzyme 165–173
- Glucocorticoids**  
inflammation, gene transcription 557–572\*  
prenatal exposure, hypertension 149–155
- Glucose metabolism**  
adipose tissue, lipolysis 71–77
- Glucose tolerance test**  
hypertension, insulin resistance 609–614
- Glucose uptake**  
*N*<sup>G</sup>-monomethyl-L-arginine, nitric oxide synthase 175–180
- Glutaminase distribution**  
gastrointestinal tract, glutamine synthetase 313–319
- Glutamine**  
gastrointestinal tract, glutamine synthetase 313–319
- Glutamine synthetase**  
gastrointestinal tract, glutaminase distribution 313–319
- Glutathione peroxidase**  
diabetes, oxidative stress 623–632  
oxidative stress, elderly 447–452
- Glycation**  
bile-salt-dependent lipase, albumin 181–188
- Glycopolypeptides**  
gastric carcinoma 87–99
- Granulocyte pool**  
pulmonary circulation, lung 7–19\*
- Gut**  
glutaminase distribution, glutamine synthetase 313–319
- Haematopoiesis**  
leptin, adolescents 633–636
- Haemodiafiltration**  
body mass index, leptin 431–435
- Haemodialysis**  
obesity, leptin 431–435
- Haemodynamics**  
portal hypertension, octreotide 645–650  
temperature, elderly 493–498
- Haemorrhagic telangiectasia**  
adenosine deaminase deficiency, polymorphism 207–218\*
- Head-up tilt**  
temperature, haemodynamics 493–498
- Heart failure**  
adrenomedullin, gene expression 359–365  
L-arginine transport, erythrocytes 3–4, 43–48  
coronary flow reserve, exercise capacity 485–492  
natriuretic peptides,  
renin-angiotensin-aldosterone system 591–599
- Heart muscle**  
ATP synthase, mitochondrion 499–504
- Heart rate variability**  
aerobic exercise, aging 579–584  
chronic fatigue syndrome, blood pressure 57–63  
diabetes, adolescents 615–621

- Hepatic injury  
carbon tetrachloride, epidermal growth factor 219–223
- High-density lipoprotein  
oxidation,  $\beta$ -blockers 573–578
- High-flux haemodialysis  
body mass index, leptin 431–435
- HLA-DQB1 alleles  
diabetes, genetic susceptibility 263–269
- 5-Hydroxytryptamine  
small intestine, gastrointestinal motility 663–670
- Hypercholesterolaemia  
vitamin E, endothelial dysfunction 129–134
- Hyperdynamic circulation  
portal hypertension, octreotide 645–650
- Hyperinsulinaemia  
hypertension, blood pressure 609–614
- Hypertension  
angiotensin-converting enzyme inhibitor, maternal undernutrition 337–338, 373–381  
angiotensin-converting enzyme inhibitors, diabetic nephropathy 511–516  
baroreflex sensitivity, elderly 245–253  
coronary arteries, acetylcholine 231–238  
endothelium-dependent vasodilatation, noradrenaline 601–607  
glucocorticoids, prenatal exposure 149–155  
insulin resistance, blood pressure 609–614  
membrane microviscosity, calcium 79–85  
myogenic tone, nitric oxide 225–229  
vasopressin receptors 517–523
- Hypertriglyceridaemia  
membrane microviscosity, erythrocytes 79–85
- Hypertrophic cardiomyopathy  
adrenomedullin, natriuretic peptides 21–28  
venous capacitance, hypotension 335–336, 339–346
- Hypertrophic scar tissue  
fibroblasts, decorin 541–547
- Hyperventilation  
isometric exercise, cerebral blood flow 353–358
- Hypoglycaemia  
cerebral dysfunction, lactate 157–163
- Hypophosphatasia  
alkaline phosphatase, pyridoxal-5'-phosphate 203–206
- Hypotension  
gastric emptying, diabetes mellitus 65–70  
venous capacitance, hypertrophic cardiomyopathy 335–336, 339–346
- Hypoxaemia  
muscle fatigue,  $^{31}\text{P}$  magnetic resonance spectroscopy 279–286
- Hypoxia  
bronchial occlusion, pulmonary blood flow distribution 453–460
- Idiopathic pulmonary fibrosis  
bronchoalveolar lavage fluid, cytokeratins 531–535
- Immune response  
neutrophil priming, superoxide anions 461–471\*
- Immunoassay  
vascular endothelial growth factor 395–404
- Immunodeficiency  
adenosine deaminase deficiency, genetic mutation 207–218\*
- Indomethacin  
myogenic tone, hypertension 225–229
- Infection  
protein metabolism, acute phase proteins 413–423
- Inflammation  
diabetic neuropathy, total skin blood flow 255–261  
glucocorticoids, gene transcription 557–572\*  
neutrophil priming, phosphoinositide 3-kinase 461–471\*
- Inflammatory bowel disease  
genetic susceptibility, Crohn's disease 473–478\*  
leptin, body fat 479–483
- Inflammatory response  
adhesion molecule-1, circadian rhythm 537–540
- Insulin  
leptin, body mass index 633–636
- Insulin resistance  
blood pressure, hypertension 609–614
- Insulin sensitivity  
nitric oxide, blood flow 175–180
- Interstitial lung disease  
bronchoalveolar lavage fluid, cytokeratins 531–535
- Intestinal-type metaplasia  
mucins 87–99
- Intrauterine factors  
hypertension, captopril 337–338, 373–381
- Intraventricular haemorrhage  
total antioxidant status, preterm infants 197–201
- Ischaemia  
muscle contractility, preservation solutions 271–278

- Isometric exercise**  
 hyperventilation, cerebral blood flow 353–358  
 muscle sympathetic activity, adrenaline 383–393
- Isosorbide dinitrate**  
 portal hypertension, haemodynamics 645–650
- Kidney vasopressin receptors**  
 deoxycorticosterone acetate-salt hypertension, gene transcription 517–523
- Lactate**  
 diabetes, cerebral dysfunction 157–163
- Lactate extraction**  
 myocardial ischaemia, atrial pacing 29–34
- Lactate metabolism**  
 skeletal muscle, carbohydrate ingestion 71–77
- Lactation**  
 bone mineral density 405–412
- Leptin**  
 acquired immunodeficiency syndrome, anorexia 479–483  
 haematopoiesis, adolescents 633–636  
 obesity, haemodialysis 431–435
- Linkage studies**  
 adenosine deaminase deficiency, haemorrhagic telangiectasia 207–218\*
- Lipid**  
 cardiopulmonary bypass, oxygen 1, 35–41
- Lipid-associated oxygen**  
 cardiac surgery, blood 1, 35–41
- Lipid peroxidation**  
 coronary disease,  $\beta$ -blockers 573–578  
 preterm infants, antioxidant status 197–201
- Lipolysis**  
 adipose tissue, glucose metabolism 71–77
- Lisinopril**  
 proteinuria, renal tubular injury 425–430
- Liver**  
 oxidative stress, diabetes 623–632
- Liver damage**  
 carbon tetrachloride, epidermal growth factor 219–223
- Liver vasopressin receptors**  
 deoxycorticosterone acetate-salt hypertension, gene transcription 517–523
- Loop diuretics**  
 natriuretic response, metabolic alkalosis 287–292, 687
- Low-density lipoprotein**  
 oxidation,  $\beta$ -blockers 573–578  
 peroxidation, myocardial ischaemia 29–34
- Lung**  
 bronchial occlusion, pulmonary flow distribution 453–460  
 granulocyte pool, pulmonary circulation 7–19\*
- Lymphocytes**  
 oxidative stress, elderly 447–452
- Lympho-mononuclear cells**  
 cirrhosis, *N*<sup>o</sup>-nitro-L-arginine methyl ester 637–643
- Magnetic resonance spectroscopy**  
 muscle fatigue, hypoxaemia 279–286
- Major histocompatibility complex**  
 Crohn's disease, genetic susceptibility 473–478\*
- Malnutrition**  
 tuberculosis, protein metabolism 321–331
- Malondialdehyde**  
 antioxidant status, preterm infants 197–201
- Maternal undernutrition**  
 hypertension, angiotensin-converting enzyme inhibitor 337–338, 373–381
- Matrix deposition**  
 matrix metalloproteinases, atherosclerosis 103–110\*
- Matrix metalloproteinases**  
 vascular matrix remodelling, atherosclerosis 103–110\*
- Membrane microviscosity**  
 hypertension, calcium 79–85
- Menstruation**  
 bone mineral density, pregnancy 405–412
- Metabolic alkalosis**  
 bumetanide, natriuretic response 287–292, 687
- Metabolic effects**  
 muscle fatigue, hypoxaemia 279–286
- Methacholine**  
 cold exposure, asthma 525–529
- Methylation**  
 protein, brain 677–685
- Microalbuminuria**  
 angiotensin-converting enzyme, diabetes 165–173
- Microspheres**  
 bronchial occlusion, pulmonary flow distribution 453–460
- Migrating motor complex**  
 small intestine, 5-hydroxytryptamine 663–670
- Mitochondrion**  
 ATP synthase, heart muscle 499–504
- N*<sup>o</sup>-Monomethyl-L-arginine**  
 nitric oxide synthase, glucose uptake 175–180  
 erythrocytes, heart failure 3–4, 43–48

- Mucins**  
gastric carcinoma 87–99
- Muscle**  
ATP synthase, mitochondrion 499–504
- Muscle contractility**  
preservation solutions, ischaemia 271–278
- Muscle fatigue**  
<sup>31</sup>P magnetic resonance spectroscopy, hypoxaemia 279–286
- Muscle sympathetic activity**  
adrenaline, isometric exercise 383–393
- Myocardial hypertrophy**  
coronary arteries, nitric oxide 141–147
- Myocardial infarction**  
adrenomedullin, natriuretic peptides 135–139
- Myocardial ischaemia**  
thromboxane, atrial pacing 29–34
- Myoelectrical effects**  
muscle fatigue, hypoxaemia 279–286
- Myogenic tone**  
coronary arteries, acetylcholine 231–238  
hypertension, nitric oxide 225–229
- Natriuretic peptides**  
adrenomedullin, myocardial infarction 135–139  
gene expression, heart failure 359–365  
heart failure, renin–angiotensin–aldosterone system 591–599  
hypertrophic cardiomyopathy, adrenomedullin 21–28
- Natriuretic response**  
metabolic alkalosis, bumetanide 287–292, 687
- Necrotizing acute pancreatitis**  
sodium taurocholate, zymogen granules 293–301
- Neurogenic inflammation**  
diabetes, total skin blood flow 255–261
- Neuropeptide Y**  
heart failure 591–599
- Neurovascular stimulation**  
diabetes, nutritive capillary blood flow 255–261
- Neutrophil cathepsin G**  
platelet–neutrophil adhesion, platelet P-selectin 437–445
- Neutrophil priming**  
immune response, superoxide anions 461–471\*
- Nitric oxide**  
cardiopulmonary bypass, aprotinin 505–509  
cirrhosis, peripheral vascular resistance 637–643  
coronary arteries, endothelium-dependent relaxation 231–238  
coronary arteries, myocardial hypertrophy 141–147  
endothelium-dependent dilatation, Raynaud's disease 239–243  
insulin sensitivity, blood flow 175–180  
myogenic tone, hypertension 225–229
- Nitric oxide synthase**  
glucose uptake, N<sup>G</sup>-monomethyl-L-arginine 175–180
- N<sup>G</sup>-Nitro-L-arginine**  
coronary arteries, chronic ischaemic myocardial remodelling 141–147
- N<sup>ω</sup>-Nitro-L-arginine**  
myogenic tone, hypertension 225–229
- N<sup>ω</sup>-Nitro-L-arginine methyl ester**  
cirrhosis, nitric oxide synthase 637–643
- Nitroprusside**  
baroreflex sensitivity, blood pressure 245–253  
endothelial dysfunction, hypercholesterolaemia 129–134
- Noradrenaline**  
endothelium-dependent vasodilatation, hypertension 601–607  
hypertrophic cardiomyopathy, adrenomedullin 21–28  
insulin resistance, hypertension 609–614
- Noradrenaline release**  
muscle sympathetic activity, adrenaline 383–393
- Nuclear factor κB**  
glucocorticoids, gene transcription 557–572\*
- Nutrition**  
haemodialysis, leptin 431–435
- Nutritive capillary blood flow**  
neurovascular stimulation, diabetes 255–261
- Obesity**  
leptin, haematopoiesis 633–636  
leptin, haemodialysis 431–435  
thermogenesis, cardiovascular response 121–127
- Octreotide**  
insulin resistance, hypertension 609–614  
portal hypertension, cirrhosis 367–371  
portal hypertension, haemodynamics 645–650
- Orthostatic hypotension**  
autonomic failure 347–352
- Osteogenesis**  
colony forming units–fibroblastic, aging 549–555
- Osteoporosis**  
aging, colony forming units–fibroblastic 549–555

- Oxidation  
low-density lipoprotein,  $\beta$ -blockers 573–578
- Oxidative stress  
diabetes, liver 623–632  
lymphocytes, elderly 447–452
- Oxygen  
cardiac surgery, plasma lipid 1, 35–41
- Oxygen free-radicals  
diabetes, antioxidant enzymes 623–632
- Painful crisis  
sickle cell disease, cooling 111–120
- Pancreas  
oxidative stress, diabetes 623–632
- Pancreatitis  
sodium taurocholate, zymogen granules 293–301
- Peripheral vascular resistance  
nitric oxide, cirrhosis 637–643
- Peroxidation  
myocardial ischaemia, low-density lipoprotein 29–34
- Phenylephrine  
baroreflex sensitivity, blood pressure 245–253
- Phosphoinositide 3-kinase  
neutrophil priming, inflammation 461–471\*
- Phospholipase D  
neutrophil priming, inflammation 461–471\*
- Platelet–neutrophil adhesion  
platelet P-selectin, neutrophil cathepsin G 437–445
- Platelet P-selectin  
platelet–neutrophil adhesion, neutrophil cathepsin G 437–445
- Platelets  
vascular endothelial growth factor, blood clotting 395–404
- Pneumonitis  
bronchoalveolar lavage fluid, cytokeratins 531–535
- Polymorphism  
haemorrhagic telangiectasia, adenosine deaminase deficiency 207–218\*
- Portal hypertension  
cirrhosis, octreotide 367–371  
haemodynamics, octreotide 645–650
- Portal hypertensive gastropathy  
cirrhosis, octreotide 367–371
- Portal vein stenosis  
octreotide, hyperdynamic circulation 645–650
- Postprandial hypotension  
gastric emptying, diabetes mellitus 65–70
- Postural hypotension  
head-up tilt, temperature 493–498
- Potassium  
blood specimens 101
- Power spectral analysis  
diabetes, adolescents 615–621  
heart rate variability, chronic fatigue syndrome 57–63
- Pregnancy  
bone mineral density 405–412
- Prenatal exposure  
glucocorticoids, hypertension 149–155
- Preservation solutions  
muscle contractility, ischaemia 271–278
- Pressoreceptors  
baroreflex sensitivity, hypertension 245–253
- Preterm infants  
antioxidant status, lipid peroxidation 197–210
- Prostacyclin  
myocardial ischaemia, atrial pacing 29–34
- Protein carboxymethylation  
brain 677–685
- Protein diet  
fetal exposure, hypertension 337–338, 373–381
- Protein metabolism  
infection, acute phase proteins 413–423  
tuberculosis, wasting 321–331
- Protein oxidative damage  
elderly, oxidative stress 447–452
- Protein synthesis  
sepsis, acute phase proteins 413–423  
tuberculosis, wasting 321–331
- Proteinuria  
diabetes, angiotensin-converting enzyme 165–173  
renal tubular injury, lisinopril 425–430
- Proteoglycans  
hypertrophic scar tissue, burns 541–547
- Proximal tubular hypercatabolism  
proteinuria, lisinopril 425–430
- P-selectin  
platelet–neutrophil adhesion, neutrophil cathepsin G 437–445
- Pulmonary arteriovenous malformations  
linkage studies, haemorrhagic telangiectasia 207–218\*
- Pulmonary circulation  
granulocyte pool, lung 7–19\*
- Pulmonary flow distribution  
bronchial occlusion, blood gases 453–460
- Pulmonary inflammation  
nitric oxide, aprotinin 505–509
- Pyridoxal-5'-phosphate  
hypophosphatasia, alkaline phosphatase 203–206

- Raynaud's disease  
nitric oxide, endothelium-dependent dilatation 239–243
- Reflex venoconstriction  
hypertrophic cardiomyopathy, exercise-induced hypotension 335–336, 339–346
- Renal response  
bumetanide 287–292, 687
- Renal tubular injury  
proteinuria, lisinopril 425–430
- Renin–angiotensin–aldosterone system  
heart failure, natriuretic peptides 591–599
- Respiratory disease  
adenosine deaminase deficiency, polymorphism 207–218\*
- Respiratory sinus arrhythmia  
heart rate variability, aerobic exercise 579–584
- Retinol  
diabetes, dietary supplements 189–195
- Retinopathy of prematurity  
total antioxidant status, preterm infants 197–201
- Sarcoidosis  
bronchoalveolar lavage fluid, cytokeratins 531–535
- Sepsis  
protein synthesis, acute phase proteins 413–423
- Serotonin  
small intestine, gastrointestinal motility 663–670
- Shear stress  
endothelium-dependent dilatation, Raynaud's disease 239–243
- Sickle cell disease  
cooling, vascular response 111–120
- Skeletal muscle  
glucose metabolism, lipolysis 71–77  
isometric exercise, cerebral blood flow 353–358
- Skin cooling  
airway obstruction, asthma 525–529
- Small intestine  
5-hydroxytryptamine, gastrointestinal motility 663–670
- Sodium excretion  
bumetanide, metabolic alkalosis 287–292, 687
- Sodium taurocholate  
zymogen granules, pancreatitis 293–301
- Spectrum analysis  
baroreflex sensitivity, hypertension 245–253
- Stomach  
mucins, tumour 87–99
- Strain-gauge plethysmography  
deep venous thrombosis, duplex scanning 651–656
- Stroke volume  
orthostatic hypotension, autonomic failure 347–352
- Stromelysin expression  
atherosclerosis, polymorphism 103–110\*
- Superoxide anions  
neutrophil priming, immune response 461–471\*
- Superoxide dismutase  
diabetes, oxidative stress 623–632  
oxidative stress, elderly 447–452
- Surface electromyogram  
muscle fatigue, hypoxaemia 279–286
- Sympathetic denervation  
exercise, blood pressure 5, 49–55
- Sympathetic nerves  
adrenaline infusion, noradrenaline release 383–393
- Syncope  
venous capacitance, hypertrophic cardiomyopathy 335–336, 339–346
- Temperature  
haemodynamics, elderly 493–498
- Thermogenesis  
adrenaline, energy expenditure 121–127
- Thiobarbituric acid-reactive substances  
diabetes, oxidative stress 623–632
- Thrombin  
platelet–neutrophil adhesion, platelet P-selectin 437–445
- Thromboxane  
myocardial ischaemia, atrial pacing 29–34
- Tocopherols  
diabetes, dietary supplements 189–195  
endothelial dysfunction, hypercholesterolaemia 129–134
- Total skin blood flow  
neurogenic inflammation, diabetes 255–261
- Transforming growth factor  $\beta$   
hypertrophic scar tissue, decorin 541–547
- Transoesophageal Doppler echocardiography  
coronary flow reserve, dilated cardiomyopathy 485–492
- Transplantation  
muscle contractility, preservation solutions 271–278
- Trimethylamino-diphenylhexatriene anisotropy  
membrane microviscosity, erythrocytes 79–85
- Trypsinogen  
zymogen granules, pancreatitis 293–301

- Tuberculosis  
  undernutrition, anabolic block 321–331
- Tumour  
  stomach, mucins 87–99
- Tumour growth  
  dietary lipids, colon cancer 303–311
- Ulcerative colitis  
  genetic linkage, Crohn's disease 473–478\*
- Undernutrition  
  tuberculosis, anabolic block 321–331  
  tuberculosis, protein metabolism 321–331
- Upper limb venous thrombosis  
  colour Doppler sonography 657–661
- Urokinase  
  colonic epithelium, butyrate enema 671–676
- Vascular endothelial growth factor  
  platelets, blood clotting 395–404
- Vascular matrix remodelling  
  matrix metalloproteinases, atherosclerosis  
  103–110\*
- Vascular permeability factor  
  platelets, blood clotting 395–404
- Vascular resistance  
  blood pressure, autonomic failure 347–352
- Vascular response  
  sickle cell disease, cooling 111–120
- Vascular smooth muscle  
  myogenic tone, nitric oxide 225–229
- Vasoactive hormones  
  heart failure, gene expression 359–365
- Vasoconstrictor  
  endothelium-dependent relaxation,  
  hypertension 231–238
- Vasodilatation  
  hypertension, noradrenaline 601–607
- Vasopressin receptors  
  deoxycorticosterone acetate-salt hypertension  
  517–523
- Venous capacitance  
  hypotension, hypertrophic cardiomyopathy  
  335–336, 339–346
- Venous thrombosis  
  colour Doppler sonography 657–661
- Vitamin B<sub>6</sub>  
  alkaline phosphatase, hypophosphatasia  
  203–206
- Vitamin E  
  endothelial dysfunction, hypercholesterolaemia  
  129–134
- Wasting  
  tuberculosis, protein metabolism 321–331
- Zymogen granules  
  enzyme content, pancreatitis 293–301